CA-ANDERSEN-GLOBAL
10.6.2022 12:17:06 CEST | Business Wire | Pressemeddelelse
Andersen Global fortsætter sin ekspansion på det nordiske marked gennem samarbejdsaftaler med det danske advokatfirma Bachmann/Partners og det finske advokatfirma I&O Partners. Med udgangspunkt i de eksisterende samarbejdende virksomheder Hellström Law og Unum i Sverige og Braekhus i Norge, styrker disse tilføjelser organisationens omfattende og integrerede skattemæssige og juridiske dækning i regionen.
Med kontorer i København og Aarhus tilbyder Bachmann/Partners en bred vifte af tjenester, herunder skattestrid og rådgivning, moms, punktafgifter, strafferetlig skatteret, arve- og ejendomsplanlægning for private og familieejede virksomheder med stor formue, international skatte- og erhvervsret. Bachmann/Partners, som er anerkendt af The Legal 500 som en konkurrencedygtig virksomhed i regionen, blev grundlagt i 2016 af ledende partner Christian Bachmann og leverer tjenester til lokale og internationale kunder.
”Vi har gennem årene opbygget vores omdømme på baggrund af vores store kendskab til dansk erhvervsliv, især vores specialisering i alle skatteretlige forhold”, siger Christian. ”Vi ser frem til at arbejde sammen med medlemsvirksomhederne og de samarbejdende virksomheder i Andersen Global, samtidig med at vi fastholder en konkurrencefordel på markedet og leverer omfattende løsninger til kunder globalt”.
I&O Partners blev grundlagt i 2015 og bistår kunder inden for områder som bank og finans, virksomhedsrådgivning, erhverv, tvistbilæggelse, ansættelse, fusioner og opkøb, IP-teknologi, omstrukturering og privat formue. Under ledelse af ledende partner Andrei Aganimov arbejder virksomhedens team på mere end 16 fagfolk tæt sammen med nationale og internationale virksomheder såvel som private kunder.
”Virksomheden er vokset ret hurtigt siden vores grundlæggelse for næsten syv år siden, og vores samarbejde med Andersen Global er næste skridt i vores vækst og udvikling”, siger Andrei. ”Vores samarbejde positionerer os til at udnytte den kollektive styrke i en global organisation, overgå kundernes forventninger og levere problemfri service”.
”Bachmann/Partners og I&O Partners deler et stærkt engagement i klassens bedste service og en passion for forvaltning og gennemsigtighed”, siger Andersen Globals bestyrelsesformand og CEO Mark Vorsatz. ”Deres teams vil være et stort aktiv til at imødekomme vores kunders voksende behov og vil arbejde synergistisk med medlemsvirksomhederne og de samarbejdende virksomheder i Andersen Global, samtidig med at vi fortsætter med at udbygge vores kapacitet i Nordeuropa”.
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer, bestående af skatte- og juraeksperter i hele verden. Andersen Global blev stiftet af den amerikanske medlemsvirksomhed Andersen Tax LLC i 2013 og Andersen Global har nu over 11.000 fagfolk globalt og er repræsenteret på mere end 360 lokaliteter via sine medlemsvirksomheder og samarbejdende virksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220609005325/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum